Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Cytogenetic evolution patterns in CML post-SCT.

  • Kristina Karrman
  • B Sallerfors
  • S Lenhoff
  • Thoas Fioretos
  • Bertil Johansson
Publishing year: 2007
Language: English
Pages: 165-171
Publication/Series: Bone Marrow Transplantation
Volume: 39
Issue: 3
Document type: Journal article
Publisher: Nature Publishing Group

Abstract english

The cytogenetic evolution patterns in chronic myeloid leukemia (CML) after allogeneic ( allo) stem cell transplantation (SCT) are different from the ones observed in non-transplanted patients, a phenomenon suggested to be caused by the conditioning regime. We reviewed 131 CMLs displaying karyotypic evolution after SCT (122 allo, nine autologous (auto)), treated at Lund University Hospital or reported in the literature. Major route abnormalities (i.e., +8, +Ph, i(17q), +19, +21, +17 and -7) were seen in 14%, balanced aberrations in 61%, hyperdiploidy in 19%, pseudodiploidy in 79%, divergent clones in 14%, and Ph-negative clones in 21%. The breakpoints involved in secondary structural rearrangements clustered at 1q21, 1q32, 7q22, 9q34, 11q13, 11q23, 12q24, 13q14, 17q10 and 22q11. Cytogenetic abnormalities common in AML after genotoxic exposure, that is, der(1;7)(q10; p10), del(3p), -5, del(5q), -7, -17, der(17p), -18, and -21, were only rarely seen post-SCT. Comparing the cytogenetic features in relation to type of SCT revealed that balanced aberrations were significantly more common after allo than after auto SCT (64 and 22%, respectively, P = 0.03). In addition, there was a trend as regards hyperdiploidy being more common after auto (P = 0.07) and pseudodiploidy being more frequent after allo SCT (P = 0.09). Possible reasons for these differences are discussed.


  • Medical Genetics
  • Hematology
  • allogeneic
  • chronic myeloid leukemia
  • autologous
  • stem cell
  • transplantation
  • cytogenetic evolution


  • ISSN: 1476-5365
Thoas Fioretos
E-mail: thoas.fioretos [at]

Principal investigator

Division of Clinical Genetics

+46 46 222 45 95

+46 70 334 33 67